A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs (ENABLE-2)
A Phase 3, Multicenter, Open-Label, Randomized Study of ELVN-001 Versus Investigator-Selected Tyrosine Kinase Inhibitor (TKI) of Dasatinib, Nilotinib, or Bosutinib, in Adult Participants With Chronic Myeloid Leukemia in Chronic Phase (CP-CML), Previously Treated With One or More TKIs
The study is designed to compare the efficacy of ELVN-001 versus Investigator-selected tyrosine kinase inhibitor (TKI) for adults with previously treated chronic myeloid leukemia in the chronic phase (CP-CML). The Investigator-selected TKI will be one of the following standard of care therapies: Dasatinib, Nilotinib, or Bosutinib.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
This is a multicenter, open-label, randomized study of ELVN-001 versus Investigator-selected TKI (Dasatinib, Nilotinib, or Bosutinib) in adult participants with CP-CML previously treated with one or more TKIs. Participants will be randomized to receive either ELVN-001 or their investigator's choice of one of the comparator TKIs (Dasatinib, Nilotinib, or Bosutinib). Treatment will continue until one of the protocol defined treatment discontinuation criteria are met. Participants will then enter a long-term follow-up period for survivorship and updates on disease status.
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Enliven Medical Information
- Telefonnummer: +1 6505475814
- E-post: MedInfo@enliventherapeutics.com
Studiesteder
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Rekruttering
- Winship Cancer Institute
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46260
- Rekruttering
- Investigative Clinical Research of Indiana, LLC
-
-
New Jersey
-
Morristown, New Jersey, Forente stater, 07960
- Rekruttering
- Atlantic Health System
-
-
Utah
-
Ogden, Utah, Forente stater, 84405
- Rekruttering
- Community Center Trials of Utah
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Male or female at least 18 years of age
- Diagnosis of chronic myeloid leukemia in chronic phase (CP-CML)
- Prior treatment with 1 or more BCR::ABL1 TKI(s)
- Failure or intolerance on the immediate prior TKI
- Adequate end organ function as measured by blood tests
Exclusion Criteria:
- Known T315I mutation
- Known second chronic phase of CML after previous progression to accelerated or blast phase
- Any serious or uncontrolled medical disorder
- QT interval corrected by Fridericia's formula (QTcF) ≥ 470 msec
- Previous treatment with a hematopoietic stem-cell transplantation
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: ELVN-001
ELVN-001 |
ELVN-001 orally daily |
|
Aktiv komparator: Investigator-selected TKI
Randomized to receive one of the following investigator's choice TKIs: Dasatinib, Nilotinib, or Bosutinib |
TKI orally daily
Andre navn:
|
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Major Molecular Response (MMR) Rate at Week 24 - ELVN-001 versus Investigator-selected TKI
Tidsramme: 24 weeks
|
Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale. |
24 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Major Molecular Response (MMR) Rate at Week 96 - ELVN-001 versus Investigator-selected TKI
Tidsramme: 96 weeks
|
Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale. |
96 weeks
|
|
Change in overall scores, individual scales, and health status based on participant reporting - ELVN-001 versus Investigator-selected TKI
Tidsramme: planned total follow-up duration of 5 years
|
Validated questionnaires will be used to assess disease-related symptoms, functioning, and tolerability. |
planned total follow-up duration of 5 years
|
|
Major Molecular Response (MMR) at all scheduled collection time points - ELVN-001 versus Investigator-selected TKI
Tidsramme: planned total follow-up duration of 5 years
|
Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale |
planned total follow-up duration of 5 years
|
|
Major Molecular Response (MMR) by all scheduled collection time points - ELVN-001 versus Investigator-selected TKI
Tidsramme: planned total follow-up duration of 5 years
|
Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale |
planned total follow-up duration of 5 years
|
|
Time to Major Molecular Response (MMR) - ELVN-001 versus Investigator-selected TKI
Tidsramme: planned total follow-up duration of 5 years
|
The time to MMR is defined as the time from the date of randomization to the date of the first documented occurrence of MMR |
planned total follow-up duration of 5 years
|
|
Duration of Major Molecular Response (MMR) - ELVN-001 versus Investigator-selected TKI
Tidsramme: planned total follow-up duration of 5 years
|
Duration of MMR is defined as the time between the date of the first achievement of MMR and the earliest date of loss of MMR or CML-related death |
planned total follow-up duration of 5 years
|
|
BCR::ABL1 ratio ≤ 1% at and by all scheduled data collection time points - ELVN-001 versus Investigator-selected TKI
Tidsramme: planned total follow-up duration of 5 years
|
BCR::ABL1 transcript levels are measured by quantitative polymerase chain reaction (qPCR). The ratio is calculated for BCR::ABL/ABL1 based on the International Scale |
planned total follow-up duration of 5 years
|
|
Time to treatment failure - ELVN-001 versus Investigator-selected TKI
Tidsramme: planned total follow-up duration of 5 years
|
Time to treatment failure is defined as the time from randomization to the first date of any of the following events: treatment failure as defined per protocol |
planned total follow-up duration of 5 years
|
|
Progression-free survival - ELVN-001 versus Investigator-selected TKI
Tidsramme: planned total follow-up duration of 5 years
|
Progression-free survival is defined as the time from randomization to the earliest occurrence of progression or death from any cause |
planned total follow-up duration of 5 years
|
|
Overall survival (OS) - ELVN-001 versus Investigator-selected TKI
Tidsramme: planned total follow-up duration of 5 years
|
OS is defined as the time from randomization to death from any cause |
planned total follow-up duration of 5 years
|
|
MR4 and MR4.5 at and by all scheduled data collection time points - ELVN-001 versus Investigator-selected TKI
Tidsramme: planned total follow-up duration of 5 years
|
Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MR4 is defined as a ratio BCR::ABL/ABL1 ≤ 0.01% on the International Scale and MR4.5 is defined as a ratio BCR::ABL/ABL1 ≤ 0.0032% on the International Scale |
planned total follow-up duration of 5 years
|
|
Time to treatment discontinuation due to adverse event (AE) - ELVN-001 versus Investigator-selected TKI
Tidsramme: planned total follow-up duration of 5 years
|
This is defined as the time from randomization to discontinuation of study treatment due to an adverse event |
planned total follow-up duration of 5 years
|
|
Characterization of adverse events (AE) and clinically relevant findings, including laboratory abnormalities, electrocardiogram (ECG) changes, and other safety data - ELVN-001 versus Investigator-selected TKI
Tidsramme: planned total follow-up duration of 5 years
|
Characteristics of AEs will be evaluated to assess safety and tolerability profiles |
planned total follow-up duration of 5 years
|
|
Plasma concentrations of ELVN-001 in participants treated with ELVN-001 will be assessed at all scheduled collection timepoints
Tidsramme: planned total follow-up duration of 5 years
|
Relevant pharmacokinetic parameters will be evaluated |
planned total follow-up duration of 5 years
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Neoplasmer
- Kronisk sykdom
- Sykdomsattributter
- Neoplasmer etter histologisk type
- Hematologiske sykdommer
- Leukemi, myeloid
- Benmargssykdommer
- Leukemi
- Myeloproliferative lidelser
- Translokasjon, genetisk
- Kromosomavvik
- Patologiske tilstander, tegn og symptomer
- Hemic og lymfatiske sykdommer
- Leukemi, myelogen, kronisk, BCR-ABL positiv
- Philadelphia kromosom
- Leukemi, Myeloid, Kronisk fase
- Svovelforbindelser
- Organiske kjemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Thiazoles
- Azoler
- Pyrimidiner
- Dasatinib
- nilotinib
- Bosutinib
Andre studie-ID-numre
Andre studie-ID-numre
- ELVN-001-301
- 2026-526266-25-00 (Ctis)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .